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Introduction: For early-stage hepatocellular carcinoma (HCC) patients, ablative
strategies are potentially curative treatment options. Stereotactic body radio-
therapy (SBRT) has emerged as a promising ablative therapy, although its
comparison with radiofrequency ablation (RFA) remains confined to a single
institution retrospective review. We sought to characterize the comparative
outcomes and cost between the two treatment strategies.
Methods: We conducted a secondary analysis of the Surveillance, Epidemiol-
ogy, and End Results (SEER)-Medicare linked database (2004–2011) and iden-
tified adult patients with stage I or II HCC and treated with RFA or SBRT as
the initial treatment within 6 months of diagnosis. Survival analysis was con-
ducted using Kaplan–Meier curves and multivariate Cox proportional hazard
analysis. Factors associated with overall survival and 90-day hospital admis-
sion post-treatment were identified using propensity score (PS) adjusted mul-
tivariate analysis. We performed costs analysis and calculated incremental
cost-effectiveness ratios (ICER).
Results: Four hundred and forty patients were identified, 408 treated with RFA
and 32 SBRT. In the overall cohort, 90-day hospitalization and 1-year mortal-
ity were similar between groups but RFA patients had better overall survival
(P < 0.001). Multivariate analysis showed advanced age, higher stage, decom-
pensated cirrhosis, and treatment with SBRT (HR 1.80; 95%CI: 1.15–2.82)
was associated with worse survival, but in the PS adjusted analysis, survival
and costs were similar between the two groups.
Conclusion: In a national cohort of early stage HCC patients, treatment with
RFA vs SBRT resulted in no significant difference in survival, 90-day hospital-
ization, or costs. These data highlight the need for a randomized clinical trial
comparing these two modalities.
Key words: comparative; HCC; ICER; RFA; SBRT.
Introduction
Hepatocellular carcinoma (HCC) is an increasingly com-
mon and highly morbid malignancy both in the United
States and worldwide.1,2 Mortality related to HCC is ris-
ing in the US due to the peak in the hepatitis C epidemic
and recent rise in non-alcohol fatty liver disease.3–5
Treatment allocation depends on several factors, includ-
ing tumour burden, liver function and overall functional
status.6 Early-stage disease is best treated by surgical
resection, liver transplantation or local ablative thera-
pies. Surgical resection is commonly contraindicated due
to presence of portal hypertension or other medical
comorbidities and liver transplantation can be limited by
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organ availability and strict candidate selection criteria.7
Thus in a large proportion of early-stage patients, local
ablative therapies are the mainstay of treatment for
early-stage HCC. Results from numerous studies show
that the most commonly applied local ablative therapy,
thermal (radiofrequency or microwave) ablation, pro-
vides local control rates of up to 80–90% for small HCCs
(< 4 cm in size).8–12 Thus, local ablative therapies can
provide an effective primary therapy.
Stereotactic body radiation (SBRT) has been pioneered
by several centres worldwide as an alternative local abla-
tive therapy for early HCC.13–15 SBRT is often used as an
alternative to RFA for patients with tumours near
anatomical structures or major vessels due to the heat-
sink effect that can occur with RFA. SBRT provides extre-
mely focused high-dose radiation to the hepatocellular
carcinoma with minimal radiation damage to the sur-
rounding liver parenchyma.16 Although initially the litera-
ture was restricted to retrospective studies, there are
now several prospective trials supporting safety and effi-
cacy of SBRT for HCC.16,17 We lack multicentre data on
SBRT efficacy and an understanding of how demographic
or health system characteristics impact treatment effec-
tiveness and survival. The population of patients with
HCC is shifting to a more elderly demographic,18 thus,
the impact of age and accumulated comorbidities on
treatment tolerability and efficacy is an important consid-
eration when making treatment decisions. Finally, we
lack understanding on real-world resource requirement
(e.g. costs, hospitalization) differences between the local
ablative therapies, as prior analyses have relied on Mar-
kov modelling based on data from a single institution.19
Thus, the aim of this study was to assess differences in
outcomes and resource requirements between local abla-
tion and SBRT using the US Surveillance, Epidemiology,
and End Results (SEER)-Medicare linked database.
Methods
Data source
We performed a secondary analysis of the SEER-Medi-
care dataset for new diagnoses of HCC (International
Classification of Diseases for Oncology, Third Edition, his-
tology codes 8170, 8172, 8173, 8174 and 8175 for HCC
and site code C22.0 for liver) from 2004–2011. The
details of SEER-Medicare data are described elsewhere.20
Per SEER-Medicare data use agreement, any reporting of
patient numbers <11 were suppressed and not displayed
in this study.
Patient selection
We included patients with American Joint Committee on
Cancer (AJCC) Stage I or II HCC who had been treated
with RFA or SBRT as their first treatment within 6 months
of diagnosis. Patients with another treatment within
30 days of RFA or SBRT were excluded, so that we could
accurately capture utilization and survival for patients
related to their treatment. Patients with missing data on
tumour stage were excluded. Patients with another
malignant primary tumour diagnosed prior to HCC diag-
nosis were excluded. Patients who had HCC diagnosed
upon death were also excluded. Those with dates of birth
that differed between CMS and SEER by more than a
year were removed from the analysis, as were any peo-
ple with autopsy or death certificate-only records.
Patients were followed until death or the end of the study
period.
Covariates
Covariates of interest included patient-level factors (age,
gender, race, comorbidities and presence of hepatic
decompensation) and system-level factors, (region of
US, residence in an urban vs rural area [as defined by
residence in a metropolitan statistical area,] and associa-
tion with liver transplant centre.) We calculated Charlson
comorbidity index using data from 12 months prior to
HCC diagnosis, excluding codes for liver disease, as pre-
viously described.21 We excluded liver disease codes
from the comorbidity index as nearly all patients had
underlying chronic liver disease, if not cirrhosis; further,
we were interested in exploring the prognostic signifi-
cance of hepatic decompensation independent of other
comorbidities. We developed a composite variable for
liver decompensation that included administrative codes
for: 1) ascites (ICD-9 789.5x) and procedural coding for
paracentesis (HCPCS 49080 - 49084); 2) hepatic
encephalopathy (ICD-9 572.2, 070.4x, 070.6x) and
medication codes from Part D for neomycin, lactulose
and rifaximin; or 3) oesophageal varices (ICD-9 456.0,
456.1, 456.2) and procedural coding for oesophagogas-
troduodenoscopy (EGD) with variceal banding (HCPCS
43205, 43244, 43251, 43999, 46934).21 We performed
a sensitivity analysis excluding oesophageal varices from
the definition of decompensation, as its inclusion without
overt variceal bleeding is controversial.
We also captured all other treatments received during
the follow-up period, including surgical resection, repeat
local ablative procedures, transarterial chemoemboliza-
tion, transarterial radioembolization, liver transplantation
or sorafenib.
Statistical analysis
The primary study outcome was overall survival of the
SBRT-treated group vs the RFA-treated group both in the
overall and propensity-matched analysis. Secondary out-
comes included 90-day hospitalization rates and overall
costs associated with each treatment strategy.
Patient characteristics were compared between treated
and control patients. The survival distributions were
reported by median and interquartile range (Q1, Q3).
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Continuous variables were compared using Wilcoxon
Signed Rank test and dichotomous variables were com-
pared using odds ratios.
We conducted Kaplan–Meier survival analysis with log-
rank tests to compare survival from the time of HCC
treatment between treatment groups. Propensity score
adjustment was used to balance the cohorts using 1:1
nearest neighbour matching accounting for differences
between the RFA-treated and SBRT-treated cohorts. The
propensity score algorithm selected the other predictor
variables by predicting the treatment variable in a logis-
tic regression. From that predicted outcome, we com-
prised a combination of the predictor variables with the
slopes and created a propensity score, and this was
used to match the treatment group subjects and discard
the remainder. We used the Hansen-Bowers measure of
global balance post-propensity score matching and
standardized differences of individual predictors to
affirm the balance. We constructed a multivariate Cox
model to identify predictors of overall survival and a
logistic regression to characterize predictors of 90-day
post-procedural hospitalization. Multivariate survival
analysis was calculated using the Cox proportional haz-
ards model. Statistical significance was defined as
P < 0.05.
We used variance inflation factors to test for collinear-
ity in the model variables with the intention of sequen-
tially removing variables where significant collinearity
was present. However, no collinearity was found in any
of our multivariate analyses, as all VIF values were less
than 5. We also tested for the interaction between rele-
vant variables (i.e. treatment and decompensation) to
determine if a stratified analysis was warranted; how-
ever, no significant interactions were seen. Deviance
residuals were examined for both Cox models to ensure
model assumptions were met. All analyses were con-
ducted in SAS 9.4 (SAS Institute, Cary NC) and R version
3.2.2. The R package “MatchIt” was used for the propen-
sity scores; the package “survival” was used for Cox Pro-
portional Hazards regression; the package “RItools” was
used for evaluation of propensity scores balance; and
“rms” was used to create the Kaplan–Meier survival
curves.22–28
Cost analysis
Total costs from the Medicare perspective were compiled
using Medicare Part A, B, and D data files from diagno-
sis to the end of follow-up. We compared costs for
SBRT-treated patient and RFA-treated patients and cal-
culated incremental cost-effectiveness ratios (ICERs) per
life-year gained. ICER is defined as the difference in
costs divided by year of life gained, and compared to
the accepted threshold of $100,000 per life-year for
cost-effective treatments.29–32 We used life-year gained
instead of quality life-year gained, as there are no avail-
able validated quality of life utility adjustments for
patients undergoing SBRT for hepatocellular carcinoma.
All costs were inflated to 2016 US dollars.
To examine the cost-effectiveness ratio, we used a
sensitivity analysis where our empirical distribution was
resampled using replacement, giving us a total of 1000
bootstrap permutations of the data. We modelled the
ICER statistic value for each of the 1000 sets of data and
plotted its cumulative density function, producing a cost-
effectiveness acceptability curve.33,34 To assess the vari-
ation of the sample, we considered the 2.5% and 97.5%
nonparametric percentiles along with its median value.
We reported the percent of bootstrap ICER values under
$100,000. A cost-effectiveness plane was plotted for
both samples, showing where the numerator and denom-
inator for the ICER lay. We conducted traditional two-
way sensitivity analyses by varying survival of the SBRT
and RFA treatment groups by 10% and 40% to test the
robustness of our sample ICER estimates.
Results
Cohort characteristics
We identified 32 SBRT-treated patients and 408 RFA-treated
patients. The characteristics of the two treatment cohorts
are shown in Table 1. The cohorts had similar gender and
stage of HCC as well as similar geographic and treating hos-
pital characteristics. SBRT-treated patients were signifi-
cantly older and had higher comorbidity but a lower
proportion of hepatic decompensation. The median follow-
up was 487 days (IQR: 403–808) for SBRT-treated patients
and 761 days (IQR: 443–1446) for RFA-treated patients.
The SBRT group received significantly less subsequent
treatments (median 1 (IQR: 1-1)) during follow-up com-
pared to the RFA group (median 1 [IQR: 1-2]) (P = 0.007).
Specifically, patients in the RFA group were more likely to
undergo subsequent liver transplantation (P < 0.001).
Survival analysis in overall cohort
In Kaplan–Meier survival analysis, SBRT patients had
worse survival than RFA-treated patients (log-rank
P < 0.001) (Fig. 1). The 1-year survival for SBRT-treated
patients was similar 78.1% respectively, compared to
79.4% for RFA-treated patients. However, 3-year sur-
vival was significantly longer in the RFA-treated cohort.
In the multivariate Cox regression model, receipt of
SBRT, age, stage II disease (vs stage I), and presence of
hepatic decompensation were associated with worse sur-
vival, while number of subsequent treatments was asso-
ciated with improved survival. (Table 2)
Survival analysis in propensity-adjusted cohort
After matching patients who underwent SBRT with those
who underwent RFA, all covariates were balanced indi-
vidually and globally, removing baseline differences
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between the groups (P = 0.779). The characteristics of
the propensity score-matched cohorts are shown in
Table S1. The median follow-up time for SBRT-treated
patients was 487 days (IQR: 403 days – 808 days) and
594 days (IQR: 434 days – 1006 days) for RFA-treated
patients.
In the propensity-matched sample, there was no sig-
nificant difference in survival between SBRT-treated and
RFA-treated patients (P = 0.30; Fig. 2). In the multivari-
ate Cox regression model, treatment in an urban setting
was associated with worse survival, while number of
treatments during follow-up was associated with
improved survival (Table S2).
90-day hospitalization
To approximate safety and resource utilization of SBRT
and RFA, we calculated 90-day post-procedural
hospitalization. The proportion of hospitalization (27.2%
SD 9.0) was higher in the RFA group than the SBRT
groups; however, this difference did not meet statistical
significance (P = 0.06). In multivariate logistic regres-
sion, predictors associated with 90-day hospitalization







Age, years, median (IQR) 77 (72,71) 73 (70, 78) 0.004
Race
White 24 (75) 236 (57.8) 0.057
Black NR 32 (7.8) 0.37
Other NR 140 (34.3) 0.008
Sex
Male 20 (62.5) 254 (62.3) 0.99
Location
Northeast NR 70 (17.2) 0.86
Midwest NR 23 (5.6) 0.054
Southern NR 61 (15) 0.55
Western 16 (50) 254 (62.3) 0.18
Urban 11 (34.4) 88 (21.6) 0.11
Care characteristics
Treated at transplant centre NR 45 (11) 0.15
Treated at teaching hospital NR 49 (12) 0.54
Tumour characteristics
Stage I NR 296 (72.5) 0.51




1 (1,2) 1 (0,1) 0.005
Decompensation NR 152 (37.3) <0.001
Additional treatments after initial SBRT or RFA
Treatment count, median (IQR) 1 (1,1) 1 (1,2) 0.007
Liver Transplantation NR 21 (5.1) <0.001
Transarterial
chemoembolization
NR 111 (27.2) 0.06
SBRT NR NR 0.78
Outcomes
1 year mortality NR 84 (20.6) 0.84
90-day hospitalization NR 111(27.2) 0.06
IQR, interquartile range; NR, not reportable per SEER-Medicare data
use agreement if cell <11. SBRT, stereotactic body radiation therapy;
RFA, radiofrequency ablation.
Fig. 1. Kaplan–Meier survival analysis in overall cohort.
Table 2. Multivariate survival analysis for the overall cohort
Hazard ratio 95% Confidence
interval
P value
SBRT (ref: RFA) 1.80 1.15–2.82 0.01
Age (years) 1.03 1.01–1.05 0.008
Male Sex (ref: Female) 0.86 0.67–1.09 0.21
Race
White 0.82 0.54–1.26 0.37
Black REF REF REF
Other 0.80 0.50–1.28 0.35
Stage II (ref: Stage I) 1.70 1.32–2.19 <0.001




Treating Centre Midwest REF REF
Treating Centre in Northeast 1.11 0.67–1.85 0.68
Treating Centre in South 0.96 0.57–1.61 0.88













RFA, radiofrequency ablation; SBRT, stereotactic body radiation ther-
apy.
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included region of the country treated (northeast; Refer-
ence: midwest), treatment at a transplant centre, stage
II disease (reference: Stage I) and higher comorbidity
index (Table S3). Treatment in an urban setting was
associated with lower risk of 90-day hospitalization.
Cost analysis
We analyzed overall and short-term (90-day) costs for
patients treated with SBRT vs RFA in both the overall
cohort and the propensity-matched cohorts. In the over-
all cohort, patients treated with RFA had significantly
higher overall costs (P = 0.002) stemming from higher
inpatient costs (Table 3). When examining 90-day costs
specifically, overall costs were similar, with SBRT patient
having a higher outpatient cost component. The median
cost per median life-year gained was similar between the
cohorts ($38,810 and $40,777). In the propensity score-
adjusted sample, overall and the 90-day costs did not
differ between treatment groups. The median cost per
life-year gained was approximately 19% higher in RFA
patients ($38,810 vs $46,253) (Table S4). Median outpa-
tient costs were higher in the SBRT group; however, this
did not translate into significant differences in overall
costs.
Both ICER point estimates show that SBRT treatment
is cost-effective compared with RFA, as they are both
lower than $100,000 per life-year gained. The full sam-
ple (n = 440) has an ICER estimate of $56,301 per life-
year gained, and the propensity score sample (n = 64)
had an estimate of $1,412 per life-year gained. In the
two-way sensitivity analysis, varying the estimate of
SBRT survival by 10%, we saw a range of ICER values
from $47,817 to $68,443. Varying by 40% gave a range
of ICER values from $32,931 to $193,908.
The full sample bootstrap median ICER was $61,164
(95% CI: -$420,299, $367,960). Since the upper confi-
dence limit was >$100,000, SBRT was not cost-effective
compared with RFA in the overall population, although
85.5% of the bootstrap ICER estimates were lower than
$100,000 (Fig. 3a). The cost-effectiveness plane
(Fig. 3b) showed the bootstrap ICER estimates mostly in
the third quadrant, which signifies that costs were lower
in the SBRT group although survival was higher in the
RFA group. In the propensity-matched sample, the med-
ian ICER estimate was $12,592 (95% CI: -$251,874,
$390,198). As in the overall cohort, the upper bound of
the 95% confidence interval exceeded $100,000, so
SBRT was not cost-effective compared to RFA; however,
92% of the bootstrap ICER estimates were lower than
$100,000 (Fig. 3c). The cost-effectiveness plane
(Fig. 3d) shows that the ICER bootstrap estimates were
centred around no difference between treatments.
Discussion
There are several local ablative therapies available for
treatment early-stage HCC patients but the literature on
comparative effectiveness and cost of the modalities is
sparse. In this analysis of elderly Medicare beneficiaries
with early-stage HCC, patients who received RFAFig. 2. Kaplan–Meier survival analysis in propensity-matched cohort.
Table 3. Median costs per patient in US dollars (2016)
SBRT (median, IQR) (n = 32) RFA (median, IQR) (n = 408) P value
Total Costs $51,746 ($27,199, $95,534) $85,016 ($46,805, $147,196) 0.002
Inpatient Costs $23,360 ($9,357, $59,624) $54,053 ($27,135, $91,653) 0.002
Outpatient Costs $30,467 ($18,073, $51,171) $27,294 ($16,737, $47,686) 0.49
Part D Medication Costs $4,400 ($1,133, $8,916) $8,201 ($2,407, $26,010) 0.07
90 Day Overall Costs $16,606 ($11,955, $22,766) $20,978 ($7,609, $41,798) 0.59
90 Day Inpatient Costs $21,201 ($17,713, $27,852) $29,126 ($16,571, $43,175) 0.44
90 Day Outpatient Costs $15,478 ($10,523, $20,469) $5,760 ($3,809, $9,167) <0.001
90 Day Part D Medication Costs $1,179 ($284, $2,717) $768 ($230, $1,853) 0.52
Median cost per median life- year gained $38,810 $40,777
IQR, interquartile range; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy.
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achieved better survival compared to patients who
underwent SBRT; however, in propensity-matched analy-
sis, overall survival was similar between patients, after
adjustment for the higher age and higher comorbidities
in patients treated with SBRT. Post-procedural hospital-
ization was numerically higher in the RFA group in the
overall sample of patients but similar in propensity-
matched analysis. Overall, our data suggest these two
treatment modalities can result in similar overall survival
and comparable costs.
Multivariate predictors of survival in the overall cohort,
including age, stage, hepatic decompensation and ability
to receive additional treatments, are consistent with
prior analyses.35 The propensity-matched multivariate
survival analysis was limited by low numbers of patients;
however, treatment in an urban setting and ability to
receive subsequent treatment remained predictors of
survival. Predictors of 90-day hospitalization included
being treated in the northwest region and being treated
at a transplant centre which could reflect referral bias of
more complex patients.
The effectiveness of SBRT and RFA for early-stage HCC
has been described in several studies. The largest retro-
spective single-centre cohort of 224 patients showed
Fig. 3. (a) Bootstrap incremental cost-effectiveness ratio distribution for the overall sample. (b) Cost-effectiveness plane for the overall sample. (c) Bootstrap
incremental cost-effectiveness ratio distribution for the propensity-matched sample. (d) Cost-effectiveness plane for the propensity-matched sample.
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equivalent tumour control between the two modalities
for tumours less than 2 cm in size; however, SBRT was
superior in achieving local tumour control for larger
tumours.36 One and two-year survival was similar
between the two groups, which is consistent with the
findings of our analysis.36 A more recent study using the
National Cancer Database of nearly 4000 patients who
received RFA and SBRT for HCC showed that RFA
patients had a superior 5-year survival in a propensity-
matched cohort.37 While the conclusions of this study dif-
fer from our findings, there are several reasons this may
be the case. The large number of patients is a strength
of this study; however, the lack of granular patient-level
data unmeasured confounders limited the level of
propensity matching that could be conducted with this
data set.37 Most importantly, the authors failed to
account for hepatic function or decompensation, which
we accounted for using diagnosis coding for hepatic
decompensation and Part D data for medications associ-
ated with hepatic decompensation.37 Finally, the authors
failed to account for subsequent loco-regional treatments
after completion of RFA or SBRT, which we were able to
adjust for in our propensity-matched analysis. These
important limitations may explain the difference in the
findings of our analysis and the results using the National
Cancer Database.37
There have been limited analyses of cost-effectiveness
of local ablative therapies for HCC. One recent Markov
model was published comparing RFA and SBRT for treat-
ment of HCC concluded that SBRTwas not a cost-effective
strategy for initial HCC treatment compared to RFA (cost
per QALY $558,679); however, SBRTwas cost-effective as
a salvage therapy in post-RFA progression.19 Our study
adds valuable real data that support the use of SBRTas an
equivalently cost-effective initial treatment when com-
pared to RFA for treatment of HCC. While overall costs
were higher in the overall RFA cohort, related to higher
inpatient costs, this could be in part explained by the pro-
longed survival seen in the RFA patients and thus added
time to accumulate costs. The costs per life-year gained
were numerically similar between the two groups in the
overall cohort; however, costs were 19% higher in the RFA
group on the PS-matched cohort. Costs were similar in the
90-day post-procedure period. Further, the propensity-
matched cohort had similar costs between the SBRT and
RFA treatment groups. In our cost-effectiveness analysis,
SBRT had an ICER below $100,000 compared to RFA in
our base case analysis. These results were consistent with
our two-way sensitivity analysis varying survival seen in
the SBRTcohort by 10%. A 40% decrease in SBRT-treated
patient survival resulted in an ICER>$100,000.
Our study has several strengths and weaknesses that
warrant attention. Our data are limited by the use of
administrative Medicare coding, which can be subject to
omission or misclassification. There were also a relatively
small number of patients in our SBRT cohort, reflecting
the still emerging use of this technology, which limits the
power of our analyses and our ability to draw strong con-
clusions on SBRT effectiveness and costs. The low num-
ber of SBRT patients is due to the strict inclusion criteria
for tumour stage and treatment within 6 months of diag-
nosis we applied to conduct this analysis. The confidence
intervals for SBRT effectiveness and costs were relatively
narrow and thus we believe this well selected cohort is
representative of patients receiving SBRT. Additionally,
there is likely selection bias for treatment with SBRT that
we could not fully account for in our propensity-based
analysis. Our hepatic decompensation variable relied on
ICD-9 coding, so not all patients with decompensation in
both groups were likely captured. SEER-Medicare data
have limited data for HCC tumour stage; the AJCC stag-
ing system is not widely endorsed for HCC due to lack of
important prognostic information including Child-Pugh
classification, alpha-foetoprotein levels and performance
status. It is possible that some patients in our analysis
had Child-Pugh class C or ECOG status 3–4, resulting in
BCLC stage D disease for whom treatment is not recom-
mended. We lacked data on quality of life, which did not
allow us to quality adjust our results for the cost-effec-
tiveness analysis. Although radiation therapy has mini-
mal impact quality of life,36 comparison studies have not
yet been performed. Our SEER-Medicare dataset only
included data through 2011; however, SBRT has become
more widely used in more recent years, thus our data
may not reflect more contemporary experience with the
use of SBRT. Finally, these data are in elderly Medicare
beneficiaries, so the data may not be applicable to
younger patients with HCC. Nonetheless, this study
examines the real-world impact and value of treatment
with SBRT and RFA.
In conclusion, our results suggest SBRT and RFA Medi-
care beneficiaries have equivalent survival and costs
when matched for baseline characteristics. A prospective
randomized clinical trial is warranted comparing these
modalities head-to-head.
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